Article
Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report.
Journal of cancer research and clinical oncology - 1 Jun 2017
Beata Sienkiewicz, Donata Urbaniak-Kujda, Jarosław Dybko, Tomasz Wróbel, Anna Wiela-Hojeńska
Abstract excerpt
PURPOSE: Voriconazole (VCZ) is a new-generation triazol antifungal agent. CYP2C19 mutations have been reported to cause variability in VCZ pharmacokinetics, and thus lead to undesirable effects of pharmacotherapy. We observed four Caucasian patients who underwent allogenic hematopoietic stem cell transplantation, treated with voriconazole for prevention of fungal infections, to establish the impact of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
